PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

Core Viewpoint - PharmAla Biotech Holdings Inc. is advancing its development of LaNeo™ MDMA and aims to initiate Phase 2a/b clinical trials in Australia, driven by increasing demand and reimbursement approvals for medical treatments using LaNeo MDMA [2]. Financial Highlights - The company has reported an increase in customer deposits, with a total of $276,000 as of August 31, 2025, up from $209,000 in 2024, and $433,000 as of November 30, 2025, up from $276,000 [7]. - Recognized revenue for the year-end 2025 was $83,000, and for Q1 2026, it was $68,000, indicating ongoing revenue generation alongside growing deposits [7]. Development and Strategy - The company has filed a short-form prospectus and secured a lending partner in Australia, which will support its clinical trial and development efforts [4]. - PharmAla is focused on alleviating the global backlog of generic, clinical-grade MDMA and developing novel drugs within the MDXX class [4].